|| List of recent Proliferation-related patents
|Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms|
The present disclosure relates to the use of the ratio between the b and a isoforms of the α6 integrin in the diagnosis of diseases associated with an altered proliferation rate, such as cancer (especially a cancer of the gastro-intestinal track), in humans.. .
Socpra Sciences Sante Et Humaines S.e.c.
|Adam-15 antibodies and immunogenic peptides|
The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and sirna molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of adam 15 and to immunogenic peptide(s) that elicits such antibodies.
|Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2|
The invention features methods of treatment and diagnosis using nrg-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel nrg-2 polypeptides and nucleic acid molecules..
Acorda Therapeutics, Inc.
|Vegf analogs and methods of use|
Modified vegf proteins that inhibit vegf-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit vegf-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders..
|Halogenated diarylacetylenes and methods of treating cancer|
Halogenated diarylacetylenes, e.g., diarylacetylenes having at least one halo substituent in one aryl ring and an amine in the opposing aryl ring, can inhibit the proliferation of ls174t colon cancer cells through the inhibition of c-myc and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21(wif1/cip1)). Such compounds are useful as antineoplastic agents..
University Of Kentucky Research Foundation
|Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof|
Disclosed are: a culture medium containing a specific growth factor and at least one phospholipid; a composition for preparation of the culture medium; a kit; and a method. A technique can be provided which uses a serum-free or low-serum culture medium and has a promoting effect on the proliferation of an animal cell comparable to the promoting effect obtained by the culture in a serum-containing culture medium..
Two Cells Co., Ltd.
|Conjugated knottin mini-proteins containing non-natural amino acids|
Disclosed are knottin peptides containing non-natural amino acids so that they can be formed by chemical conjugation into two or more knottin monomers. The knottin monomers comprise a non-natural amino acid such as an aminooxy residue within the polypeptide sequence.
The Board Of Trustees Of The Leland Stanford Junior University
|Myrtocomuloacetalone 1 as an anti inflammatory agent|
A novel compound myrtocomuloacetalone 1 (mca-1) exhibiting potent anti-inflammatory properties by inhibiting production of reactive oxygen species, including nitric oxide, superoxide, and hydrogen peroxide that effectively suppresses proliferation of t-cells and also reduces intracellular oxidative stress and inhibits nf kappa b activation.. .
|Bicyclic nitrogen-containing aromatic heterocyclic amide compound|
As a result of intensive studies on a compound having a complex i inhibitory effect and an ampk activation effect, the present inventors found that a bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention has an excellent complex i inhibitory effect and the ampk activation effect, furthermore, has a cell proliferation inhibitory effect with respect to not only human pik3ca mutation-positive breast cancer cell lines in which mct4 is not expressed but also human breast cancer cell lines which do not have mutation of pik3ca in which mct4 is not expressed, and exhibits an anti-tumor effect in a human pik3ca mutation-positive breast cancer cell line mda-mb-453 cell in a cancer-bearing mouse in which the mct4 is not expressed, thereby completing the present invention. A bicyclic nitrogen-containing aromatic heterocyclic amide compound of the present invention can be used as an agent for treating breast cancer, in particular, breast cancer in which the mct4 is not expressed, and among others, pik3ca mutation-positive breast cancer in which the mct4 is not expressed..
|5-substituted indazole-3-carboxamides and preparation and use thereof|
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of dyrk1a..
Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions.
Massachusetts Institute Of Technology
Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (pepst) and exciton-plasmon enhanced phototherapy (epep)
The use of plasmonics enhanced photospectral therapy (pepst) and exiton-plasmon enhanced phototherapy (epep) in the treatment of various cell proliferation disorders, and the pepst and epep agents and probes used therein.. .
Prebiotic effect of sialyllactose
Provided herein are prebiotic compositions comprising a combination of oligosaccharides such as sialyated oligosaccharides and fusocylated oligosaccharides, and uses thereof in stimulating the proliferation of beneficial intestinal micro biota, for example, of bifidobacteria, and/or in decreasing the abundance of enteric pathogens. The prebiotic compositions can further contain a probiotic, which can be a population of bifidobacteria, lactobacilli, bacteriodes fragilis, bacteriodes thetaiotaomicron, enterococcus faecalis (pro biotic strains thereof), staphylococcus epidermides, enterobacter aerogenes, enterobacter cloacae, or related bacteria having similar functions..
Trustees Of Boston College
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations..
Boehringer Ingelheim International Gmbh
Method for inducing il-2-free proliferation of gamma delta t cells
The present invention concerns a method of inducing il-2-free proliferation of γδ t cells using a combination of a γδ t cell activator and il-33 for use in therapy of infection, cancer, autoimmunity as well as other diseases.. .
UniversitÉ Paul Sabatier Toulouse Iii
Anti-egfrviii antibodies and uses thereof
The present invention provides antibodies that bind to the class iii variant of egfr (egfrviii) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human egfrviii with high affinity.
Regeneron Pharmaceuticals, Inc.
The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-blys antibody.
Shanghai Union Biopharm Co., Ltd
Substituted gemcitabine aryl amide analogs
In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Ohio State Innovation Foundation
Novel triazolopyrazine derivative and use thereof
The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-met tyrosine kinase activity..
Compounds and methods for delivery of prostacyclin analogs
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation
Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)
The described invention provides compositions and methods for reducing lung allograft dysfunction after lung transplant and for treating a severe pulmonary fibrosis characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The methods comprise administering to a subject in need thereof a composition comprising an antibody component comprising a therapeutic amount of an anti-cd44 antibody; and an mk2 inhibitor component comprising a therapeutic amount of an mk2 inhibitor (mk2i) polypeptide of amino acid sequence yaraaarqarakalarqlgvaa (seq id no: 1) or at least one peptide functionally equivalent to the therapeutic domain thereof selected from a polypeptide of amino acid sequence kalarqlava (seq id no: 8), a polypeptide of amino acid sequence kalarqlgva (seq id no: 9) and a polypeptide of aminoacid sequence kalarqlgvaa (seq id no: 2), or a functional equivalent thereof, and a pharmaceutically acceptable carrier..
Compositions and methods for promoting intestinal stem cell function
Disclosed herein are novel methods and compositions useful for promoting intestinal stem cell function. The methods and compositions are particularly useful for stimulating the proliferation of and/or self-renewal of intestinal stem cells, as well as for minimizing, preventing, or ameliorating cellular damage resulting from incidental or accidental exposure to radiation (e.g., cancer radiation therapy)..
Whitehead Institute For Biomedical Research
Methods and models for determining likelihood of cancer drug treatment success utilizing predictor biomarkers, and methods of diagnosing and treating cancer using the biomarkers
A method of identifying one or more biomarkers associated with one or more drugs effective to stop or repress proliferation of cancer cells, and a system for predicting effectiveness of the same. The method includes statistically analyzing (i) a first dataset of expression levels of proteins or glycoproteins in the cancer cells and (ii) a second dataset of responses of the cancer cells to drugs to identify at least one biomarker associated with effective repression of the cancer cells, and correlating or associating at least one protein or glycoprotein biomarker with a response of the cells to at least one of the drugs effective to stop or repress the proliferation of the cancer cells.
Apparatus and method to efficiently send device trigger messages
With the proliferation of machine-type communication (mtc), an excessive use of device trigger messages in a long term evolution (lte) network can have negative effects on user equipment (ue). These effect can include a shortening of ue battery life and/or excessive signalling caused by the frequent changing from an idle mode to an active mode.
Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers
The present invention relates to a method for diagnosing the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a diagnostic biomarker. The present invention also relates to a method for predicting the prognosis of the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a prognostic biomarker.
Cancer Hospital, Chinese Academy Of Medical Sciences
A method of treating a disease, disorder or condition of the eye includes irradiating the eye or eyes with a laser and subsequently detecting one or more biological responses by the eye or eyes to thereby determine the effectiveness of the laser treatment. The one or more biological responses by the eye or eyes are responses by cells, tissues and/or molecules of the eye or eyes that indicate, are associated with, or are functionally linked to, the effectiveness of the laser treatment.
Ellex Medical Pty Ltd.
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
An anti-hb-egf antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-hb-egf antibody of the present invention.
Chugai Seiyaku Kabushiki Kaisha
Wherein the groups r1 to r3 and x1 through x6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament..
Extracellular matrix compositions for the treatment of cancer
The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ecm) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent.
Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.. .
Alliant Techsystems Inc.
Semi-instantaneous microwave-induced thermo heater
Thermo heater comprising: a tank (1) made of glass, fitted with a cover (7) and a number of magnetrons (3) supported by a belt or a support framework (2) surrounding the tank (1), which offer the magnetrons continued support and which may be arranged inside the tank (1). Each one of the magnetrons (3) is housed on a primary exchanger (5) and this, in turn, on the main exchanger (6).
Functional genomics screening platform for head and neck cancer
The present invention relates to hpv-positive as well as hpv-negative screening platforms that are highly serum-dependent, for use as hnscc models. These hnscc models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the wt gene) confers enhanced cell survival and proliferation under serum deprivation.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Methods and compositions for cell-proliferation-related disorders
Methods of treating and evaluating subjects having neoactive mutants of idh (e.g., idh1 or idh2).. .
Agios Pharmaceuticals, Inc
Methods for the treatment of infections and tumors
Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.
Dana-farber Cancer Institute, Inc.
Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity. Such conditions include, but not limited to, arthritis, alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, t-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, t-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or type i diabetes, complications from diabetes, rheumatoid arthritis, asthma, crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis.
Use of mir-494 to modulate trail-induced apoptosis through bim down-regulation
Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-mir-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (tsgs) are described. Activation of the erk1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important mirnas.
Ohio State Innovation Foundation
Pharmaceutical composition comprising microrna-30b, microrna-133a, or microrna-202-5p inhibitor for inhibiting cancer
Provided is an anticancer composition, and particularly, a pharmaceutical composition for inhibiting cancer, which includes a microrna-30b, microrna-133a, or microrna-202-5p inhibitor as an active ingredient. The pharmaceutical composition may suppress microrna-30b, microrna-133a, or microrna-202-5p, thereby inhibiting proliferation of cancer cells, and eventually, is expected to be useful for cancer treatment..
Kyungpook National University Industry-academic Cooperation Foundation
Method for in vitro proliferation of cell population containing cells suitable for treatment of ischemic disease
A method of producing a cell population wherein a vascular endothelial progenitor cell and/or an anti-inflammatory macrophage are/is enriched, including cultivating a mononuclear cell derived from bone marrow, cord blood or peripheral blood in a serum-free medium containing stem cell factor, interleukin-6, fms-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and proliferating vascular endothelial progenitor cell from the cell; and a cell population obtained by the method, etc.. .
Methods and compositions for limiting viability of a modified host cell outside of designated process conditions
The invention provides methods and compositions for inhibiting proliferation of a modified host cell outside of a designated process condition. Compositions and methods for providing a host cell having reduced viability when exposed to natural conditions external to a controlled environment are disclosed..
Joule Unlimited Technologies, Inc.
Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) crbn, 2) a nucleic acid encoding crbn, or 3) a stem cell or a neural progenitor cell in which crbn is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using crbn, are provided.. .
Treatment of ocular diseases
Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.. .
Aerpio Therapeutics Inc.
Combination treatment of cancer
The present invention provides mt4-mmp inhibitor and egfr inhibitor for use in the treatment of cancer, wherein said mt4-mmp inhibitor and egfr inhibitor are different from each other. Mt4-mmp (mmp-17) is a glycosylphosphatidyl inositol (gpi) anchored mmp produced by cancer cells that promotes tumor vascularization and metastases.
UniversitÉ De LiÈge
Cd3 binding polypeptides
The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with cd3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scfvs, fabs, di-scfvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments.
Emergent Product Development Seattle Llc
A novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient is provided. The coumarin derivative or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sgag) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis..
Nippon Zoki Pharmaceutical Co., Ltd.
Stat3 inhibitors and their anticancer use
In one aspect, the invention relates to substituted 6-amino-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide analogs and derivatives thereof, substituted 4-amino-5h-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of stat protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a stat protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Research Institute At Nationwide At Children's Hospital
Lithium stimulation of cord blood stem cell proliferation and growth factor production
The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation.
Rutgers, The State University Of New Jersey
Mdm2 inhibitors for treatment of ocular conditions
Provided herein are pharmaceutical compositions for the treatment of various ocular diseases characterized by unwanted cellular proliferation. The pharmaceutical compositions may comprise one or more mdm2 inhibitors, and may further comprise one or more additional therapeutic agents.
Natural killer cells and uses thereof
Provided herein are methods of producing natural killer (nk) cells and nk progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of nk cells and nk progenitor cell populations using a three-step expansion and differentiation method.
Method for regulating cell proliferation
The present invention provides a composition for regulating cell proliferation comprising a peptide having a partial amino acid sequence of bbf2h7 or an antibody capable of binding to the peptide. The problem has been solved by preparation of the peptide having a partial amino acid sequence of bbf2h7 which has a cell proliferation activity..
Method of producing fr901228
Depsipeptides and congeners thereof are disclosed having structure (i), wherein m, n, p, q, x, r1, r2 and r3 are as defined herein. These compounds, including fr901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant.
Astellas Pharma Inc.
Preventing and reducing biofilm formation and planktonic proliferation
The present invention relates to methods for preventing and/or reducing biofilm formation and/or planktonic proliferation with one or more selected bacteria strains or bacterial blends.. .
Novozymes Biologicials, Inc.
Compounds and methods for selectively targeting cancer stem cells
Described are compounds and methods useful for selectively targeting cancer stem cells. The compounds preferentially induce differentiation and/or reduce the proliferation of cancer stem cells relative to normal stem cells.
Hematopoietic stem cell specific reporter mouse and uses thereof
Described herein are nucleic acid constructs, hematopoietic stem cell identifier animals, and methods of using thereof for isolating hematopoietic stem cell populations. Also provided are methods of using the identifier animals and cells isolated from them to screen for agents that affect the growth, proliferation, potency, expansion, or maintenance of the stem cells.
Children's Medical Center Corporaiton
Method and system for rebrokering orders in a trading system
Systems and methods are described herein for supporting the trading of bonds in a computerized system using broker dealers as intermediaries. Broker dealers receive orders relating to particular transactions and have the option to accept the order by submitting a matching counter order, or to rebroker the order with the same or modified terms to a number of other investors or additional broker dealers.
Compositions and methods for modulation of rorgammat functions
The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.
Compositions and methods for treating peripheral arterial disease
The present application discloses roles for mir-93 in treating hypoxia and ischemia. Endothelial cells (huvec) and myocytes (c2c12) expressed mir-93 and up-regulated mir-93 in response to hypoxia and serum starvation.
University Of Virginia Patent Foundation
Proliferation of muc1 expressing cells
The present application discloses a method for stimulating or enhancing proliferation of a population of cells by activating muc1 receptor on the cells.. .
Minerva Biotechnologies Corporation
Taci as an anti-tumor agent
A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a taci reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the taci reagent.. .
Biogen Idec Ma Inc.
Heterocyclic compounds and methods for their use
The present invention relates to heterocyclic compounds useful for antagonising angiotensin ii type 2 (at2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration..
Spinifex Pharmaceuticals Pty Ltd
Pharmaceutical composition of milk fat globules (mfgs) zinc free
A pharmaceutical composition comprising at least 20 wt % of milk fat globules (mgfs) and at least one c12-c20 fatty acid, and being free of zinc oxide for treating skin disorders and/or cell abnormal proliferation disorders.. .
Methods for treating cancers using oral formulations of cytidine analogs
Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents.
Substituted cc-1065 analogs and their conjugates
This invention relates to novel agents that are analogs of the dna-alkylating agent cc-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates.
Method for selectively inhibiting sulfate-reducing bacterium, gypsum composition capable of inhibiting proliferation of sulfate-reducing bacterium by said method, gypsum-type solidifying material, and gypsum-type building material
A method for performing selective bacteriostasis of a sulfate-reducing bacterium, the method selectively inhibiting proliferation of the sulfate-reducing bacterium by allowing chelated al to coexist in an environment where the sulfate-reducing bacterium exists, and a gypsum composition containing calcined gypsum (a) and chelated al (b), in which the chelated al (b) is contained in a range of 0.01 to 20 mass parts relative to 100 mass parts of the calcined gypsum (a).. .
Yoshino Gypsum Co., Ltd.
Macrocyclic compounds and methods of treatment
The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, and hdac mediated disorders.. .
University Of Florida Research Foundation
Inhibitors of bruton's tyrosine kinase
This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.
Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, btk, flt3(d835y), itk, jak1, jak2, jak3, tec and txk) and/or the respective pathways.. .
Acea Biosciences Inc.
Indole-substituted pyrrolopyrimidinyl inhibitors of uba6
Disclosed are chemical entities that inhibit uba6, each of which is a compound of formula /: formula (i) or a pharmaceutically acceptable salt thereof, wherein r*1 is —h or —ch3; and y is formula (ii) or formula (iii), wherein r2 is —h, —ch3 or c1-4 alkyloxycarbonyl; and rs7.1, rs7.2 and rs8.1 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers..
Millennium Pharmaceuticals, Inc.
Inhibitors of beta-hydroxylase for treatment of cancer
The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., asparatyl (asparaginyl) β-hydroxylase (asph)), including novel 2-aryl-5-amino-3(2h)-furanone and 2-heteroaryl-5-amino-3(2h)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of asph in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders..
Methacrylate copolymers for medical devices
A polymer of hydrophobic monomers and hydrophilic monomers is provided. It is also provided a polymer blend that contains the polymer and another biocompatible polymer.
Abbott Cardiovascular Systems Inc.
Interventional medical device and manufacturing method thereof
An interventional medical device and manufacturing method thereof. The interventional medical device comprises: a stent body (1); a surface of the stent body (1) being provided with a drug releasing structure (3), and drug in the drug releasing structure (3) being drug for suppressing proliferation of adventitial fibroblasts and a drug for suppressing proliferation of intimal and/or smooth muscle cells.
Shanghai Microport Medical (group) Co., Ltd.
Uses of il-12 in hematopoiesis
Methods for enhancing or stimulating hematopoiesis including the step of administering interleukin-12 (il-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering il-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state.
University Of Southern California
Methods and compositions for regenerating hair cells and/or supporting cells
Provided are methods and compositions for inducing cells of the inner ear (for example, cochlear and utricular hair cells) to reenter to cell cycle and to proliferate. More particularly, the invention relates to the use of agents that increase c-myc activity and/or notch activity for inducing cell cycle reentry and proliferation of cochlear or utricular hair cells and/or cochlear or utricular supporting cells.
Massachusetts Eye And Ear Infirmary
Combination therapies and methods of use thereof for treating cancer
Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.
Massachusetts Institute Of Technology